Francis Szoka, PhD
|School||UCSF School of Pharmacy|
|Address||513 Parnassus Ave|
San Francisco CA 94143
|1980||Chancellor's Award for Academic Excellence, Universiy of California, San Francisco (with Dr. Richard|
|1986||Louis W. Busse Lecturer, University of Wisconsin. Madison, Wisconsin|
|1990||Fellow of the American Association of Pharmaceutical Sciences|
|1994||Paul Neumann Prize Lecture (with Dr. Jean-Yves Legendre)|
|1995||Glaxo Lecturer, University of North Carolina, School of Pharmacy. Chapel Hill, North Carolina|
|1995||Walter F. Enz Lecturer, University of Kansas. Lawrence, Kansas|
|1995||Keynote Speaker, Pharmaceutical Chemistry Asilomar Retreat, Asilomar, California|
|1997||Controlled Release Society, Jorge Heller Outstanding Paper Award, Journal of Controlled Release. Sh|
|2000||Honorary Doctorate in Pharmacy, University of Kuopio. Kuopio, Finland. (June)|
|2000||American Association of Colleges of Pharmacy- Paul Dawson|
|2000||Biotechnology Award (July)|
|2001||America Association of Pharmaceutical Scientists- Career ResearchAchievement Award in Biotechnology |
|2006||Tenth Alec Bangham Career Achievement Award for Outstanding Liposome Research Award |
|2007||UCSF Outstanding Faculty Mentorship Award |
|2008||University of North Carolina- GlaxoSmithKline Faculty Lecturer |
|2011||Dr. Rainer Hoffman Product Through Science Award.|
The Szoka group applies chemical, biophysical and molecular biology approaches to devise vaccine, drug and nucleic acid delivery systems to treat cancer or infectious diseases. These systems can incorporate lipids, peptides, polymers and proteins. These drug carriers are composed of lipids, polymers, peptides or proteins. His group has extensively investigated the role of lipids in membrane fusion and his designed, synthesized and studied the mechanism of fusogenic peptides. With group members, he has published over 195 manuscripts and has received 26 U.S. patents. One FDA approved drug product Amphotec™ and one biotechnology product Superfect™ have been commercialized from the patents. In addition to his University commitments, Dr. Szoka is a founder of Sequus Pharmaceuticals, Inc. owned by Johnson & Johnson and GeneMedicine, inc. now known as Valentis, Inc. Sequus introduced sterically stabilized liposomes for anti-cancer drug delivery (Doxil™).
Lipids, Drug Carriers, Gene Transfer Techniques, Liposomes, HIV vaccine, Cell-based Therapies
Derived automatically from this person's publications.
People in Profiles who have published with this person.
People who share related concepts with this person.